A research team led by Dr. Kee Young Koo from the Hydrogen Research Department at the Korea Institute of Energy Research ...

Catalyst Pharmaceuticals' management shows little urgency for acquisitions, opting for share buybacks and a cautious approach ...

Ethereum has been among the biggest winners among megacap cryptocurrencies, and there are two main reasons for this.

Now, it’s worth noting Stock Advisor’s total average return is 1,076% — a market-crushing outperformance compared to 195 % ...

Nebius’s bull case hinges on the Vineland, New Jersey ramp, which directly drives ARR, power capacity, and core revenue. Learn more about NBIS stock here.

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

The S&P 500 Index had a mixed performance last week as investors reacted to corporate earnings and Fed interest rates decision ...

“It blows my mind that, at the dawn of the artificial intelligence era, our idea of revolutionary tech is to slap AI onto ...

Priorities are priorities. Upon his hiring last March, new USF men’s basketball coach Bryan Hodgson knew there was paperwork ...

A pharmaceutical company trades at 8 times forward earnings with a 7% yield as it raises revenue guidance and reenters the ...

Resources Connection stock has seen its fair value price target hold steady at $6.88 per share. Although factors like the discount rate have edged slightly lower and revenue growth estimates remain ...

Today's CFOs are more than scorekeepers; they balance control with growth to build long-term value. With a value-driven ...